Pharmacokinetics and pharmacodynamics of ciprofloxacin in cystic fibrosis patients.
about
Pharmacokinetics of ciprofloxacin in cystic fibrosis.Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosisIn vitro activity of tosufloxacin, a new quinolone, against respiratory pathogens derived from cystic fibrosis sputum.Development of a population pharmacokinetic model and optimal sampling strategies for intravenous ciprofloxacin.US Food and Drug Administration approval of ciprofloxacin hydrochloride for management of postexposure inhalational anthrax.Fluoroquinolones in the treatment of cystic fibrosis: a critical appraisal.Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: III. fluoroquinolones.The potential of liposome-encapsulated ciprofloxacin as a tularemia therapy.Pharmacokinetics of ciprofloxacin with reference to other fluorinated quinolones.Hepatic drug metabolism in cystic fibrosis: recent developments and future directions.Uncertainty and variability in human exposure limits - a chemical-specific approach for ciprofloxacin and methotrexate.Clinical utility of new quinolones in treatment of osteomyelitis and lower respiratory tract infections.Population Pharmacokinetic Modeling as a Tool To Characterize the Decrease in Ciprofloxacin Free Interstitial Levels Caused by Pseudomonas aeruginosa Biofilm Lung Infection in Wistar Rats.Ciprofloxacin: chemistry, mechanism of action, resistance, antimicrobial spectrum, pharmacokinetics, clinical trials, and adverse reactions.The future of new oral antibiotics including the quinolones.High dose treatment with antibiotics in cystic fibrosis--a reappraisal with special reference to the pharmacokinetics of beta-lactams and new fluoroquinolones in adult CF-patients.Increased oral bioavailability of ciprofloxacin in cystic fibrosis patients.Penetration of ciprofloxacin into bronchial secretions from mechanically ventilated patients with nosocomial bronchopneumonia.Utilization of salivary concentrations of ciprofloxacin in subjects with cystic fibrosis.Lack of unique ciprofloxacin pharmacokinetic characteristics in patients with cystic fibrosis.Efficacy of oral fluoroquinolones versus conventional intravenous antipseudomonal chemotherapy in treatment of cystic fibrosis.
P2860
Q33741046-F471569E-33BF-4EC3-BE27-1D75300AB53EQ33983611-D0540772-4D7B-4D6C-AE87-4C4E417053C4Q34622742-50E34BF0-C866-4B24-ADA4-B52EB563889CQ35814771-811BB907-BB78-4D36-96F1-3EFF442EDCEFQ35861305-6C8C38EA-C17D-4D73-A3AE-9D688E4221C0Q37347003-74428737-93FC-440B-BFA5-8F518BC71672Q38040734-047A5A1F-E4EA-4913-821C-48E81C02A56EQ38226279-3D622432-ADA6-4081-BCB8-15371A6DB777Q38271416-D2D08D50-83F7-41C1-B92B-BD34D729D4DAQ38566057-EE1E697B-4E68-40A0-827C-7FA129FE2EB5Q38663357-7EAD0B03-4567-4F65-98FC-A3862EED0D81Q38765037-F6B3DCE2-FCD7-4980-A2A4-F1D64E40CB50Q38810304-0B3448B0-B0CE-4727-89C7-6A28AFBF0F6DQ39214819-746D9CBD-77FB-4FCC-8AFB-2A984660B379Q39625405-35E8EB3E-79E7-4A57-BC59-F22070B08FB7Q39686183-FB262310-21D5-4D35-AFD2-FC0830F9AA69Q40284573-41D1621D-F20A-45FB-AF59-D51BC38FC57CQ40285699-80B40CF6-4AD3-4F42-9AAB-D8AFD401CBEBQ43835146-5912BDBA-EF67-46A0-BD92-FAB86882A250Q44023516-A0060EEC-CF6A-43EE-AC25-65FF8AD8BB0FQ54131581-4D3CD91C-93DA-4D38-AEE2-7635B8E0307C
P2860
Pharmacokinetics and pharmacodynamics of ciprofloxacin in cystic fibrosis patients.
description
1986 nî lūn-bûn
@nan
1986年の論文
@ja
1986年論文
@yue
1986年論文
@zh-hant
1986年論文
@zh-hk
1986年論文
@zh-mo
1986年論文
@zh-tw
1986年论文
@wuu
1986年论文
@zh
1986年论文
@zh-cn
name
Pharmacokinetics and pharmacodynamics of ciprofloxacin in cystic fibrosis patients.
@ast
Pharmacokinetics and pharmacodynamics of ciprofloxacin in cystic fibrosis patients.
@en
type
label
Pharmacokinetics and pharmacodynamics of ciprofloxacin in cystic fibrosis patients.
@ast
Pharmacokinetics and pharmacodynamics of ciprofloxacin in cystic fibrosis patients.
@en
prefLabel
Pharmacokinetics and pharmacodynamics of ciprofloxacin in cystic fibrosis patients.
@ast
Pharmacokinetics and pharmacodynamics of ciprofloxacin in cystic fibrosis patients.
@en
P2093
P2860
P356
P1476
Pharmacokinetics and pharmacodynamics of ciprofloxacin in cystic fibrosis patients.
@en
P2093
Bergeron MG
Bigonesse P
P2860
P304
P356
10.1128/AAC.30.2.260
P407
P577
1986-08-01T00:00:00Z